EUCTR2010-020352-59-GB进行中（未招募）不适用
A multi-center, placebo-controlled study to evaluate the safety of GSK716155 and its effects on myocardial metabolism, myocardial function, and exercise capacity in patients with NYHA Class II/III congestive heart failure.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Chronic heart failure due to cardiomyopathy of ischemic or non-ischemic origin.
- •2. Clinically stable on optimal therapies for at least 3 months prior to screening/baseline visit.
- •3. Left ventricular ejection fraction = 40 % as assessed by any measurement in the previous 24 months.
- •4. NYHA Class II/III heart failure for a minimum of 6 months prior to enrolment
- •5. Male or female between 21 and 75 years of age inclusive, at the time of signing the informed consent. However the optimal age range for this study will be 40 to 65
- •years of age.
- •6. A female subject is eligible to participate if she is of:
- •Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<140 pmol/L) is confirmatory]. [Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in Section 8.1 if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, method.]
- •Child-bearing potential and agrees to use one of the contraception methods listed in Section 8.1 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until the follow-up visit ~28 days post-last dose.
- •7. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- •8. Confirmed QTcB or QTcF < 480 msec; or QTc < 500 msec in subjects with Bundle
- •Branch Block.
- •9. AST and ALT < 2xULN; alkaline phosphatase and bilirubin = 1.5xULN (isolated
- •bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- •10. Subjects must be able to perform performance/exercise testing
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A subject will not be eligible for inclusion in this study if any of the following criteria apply
- •1. Active ischemia manifest as a history of myocardial infarction or unstable angina in the past 12 months or a history of coronary revascularization (percutaneous coronary intervention and/or coronary artery bypass grafting) in the past 6 months.
- •2. High suspicion of active myocardial ischemia, in the opinion of the treating physician.
- •3. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
- •result within 3 months of screening.
- •4. History of drug/alcohol abuse.
- •5. A positive test for HIV antibody.
- •6. Calcitonin > 100 pg/mL
- •7. Triglycerides > 850 mg/dL
- •8. History of significant gastrointestinal surgery, including gastric bypass and banding, antrectomy, Roux-en-Y bypass, gastric vagotomy, small bowel resection, or surgeries thought to significantlyaffect upper gastrointestinal function.
- •9. History of regular alcohol consumption within 6 months of the study defined as:
- •For UK: an average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits.
- •For US: an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits.
- •10. The subject has participated in a clinical trial and has received an investigational
- •product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the
- •investigational product (whichever is longer).
- •11. Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- •12. Known allergy or history of sensitivity to albiglutide, any other GLP-1 analogue, or
- •Baker’s yeast.
- •13. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- •14. Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
- •15. Lactating females.
- •16. Unwillingness or inability to follow the procedures outlined in the protocol (e.g.,
- •related to psychiatric disorder).
- •17. Subject is mentally or legally incapacitated.
- •18. Known diagnosis of diabetes mellitus, fasting glucose >140mg/dL, or HbA1c >7%.
- •19. Uncorrected thyroid disease manifest as an abnormal thyroid-stimulating hormone (TSH) (outside reference range at screening).
- •20. Other medical problems with life expectancy less than 1yr.
- •21. Other causes of cardiomyopathy or left ventricular dysfunction including:
- •Uncorrected primary obstructive or regurgitant valvular disease
- •Restrictive cardiomyopathy due to amyloidosis, hemochromatosis, sarcoidosis or other cause
- •Cardiac hypertrophy with wall thickness >1.5cm
- •Alcohol-induced cardiomyopathy
- •Women with heart failure during the 12 months following childbirth
- •Complex congenital heart disease
- •Anthracycline induced cardiomyopathy
- •22. Subjects with genetic disorders of skeletal muscle (e.g., Duchenne muscular
- •dystrophy).
- •23. Clinically significant pericardial disease.
- •24. Listed as a status 1A or 1B on heart transplant waiting list.
- •25. History of deep vein thrombosis or a known coagulation disorder.
- •26. History of pancreatitis.
- •27. History of or family history of medullary thyroid carcinom
研究者
相似试验
已完成
不适用
A multicentre randomised double-blind, double-dummy placebo-controlled study to assess the efficacy, safety and cost utility of Probiotic prophylaxis of spinal cord injury Urinary Tract Infection. A Therapeutic Trial. (ProSCIUTTU)People with spinal cord injury suffering from recurrent urinary tract infection resulting from multi-resistant organisms.People with stable multiple sclerosis or cerebral vascular disease, with documented neurogenic bladder on video urodynamic assessment, who also suffer from recurrent urinary tract infection resulting from multi-resitant organisms.Renal and Urogenital - Other renal and urogenital disordersInfection - Studies of infection and infectious agentsNeurological - Other neurological disordersACTRN12610000512022Dr Bon San Bonne Lee207
进行中（未招募）
不适用
A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose (1,000 mg iron) in Improving Fatigue Symptoms in Iron-deficient Non-anaemic (IDNA) Women of Child Bearing AgeEUCTR2009-017737-21-ATVifor Pharma288
进行中（未招募）
不适用
A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose (1,000 mg iron) in Improving Fatigue Symptoms in Iron-deficient Non-anaemic (IDNA) Women of Child Bearing AgeEUCTR2009-017737-21-SEVifor Pharma288
进行中（未招募）
不适用
A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose (1,000 mg iron) in Improving Fatigue Symptoms in Iron-deficient Non-anaemic (IDNA) Women of Child Bearing AgeTreatment of iron deficient non anaemic women with ferric carboxymaltose.MedDRA version: 12.1Level: LLTClassification code 10022970Term: Iron deficiencyEUCTR2009-017737-21-DEVifor Pharma288
尚未招募
不适用
Ayurvedic Rasayana therapiesCTRI/2020/07/026700Ayurved Rasayani